Buy & Sell Direxion Daily Semiconductor Bull 3X Shares (SOXL) – Direxion Daily Semiconductor Bull 3X Shares Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Leveraged / InverseSector
- -34.85%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 6 daysTypical Hold Time
Over the past 52 weeks, Direxion Daily Semiconductor Bull 3X Shares has traded between a low of $19.18 and a high of $280.18, highlighting its annual price range. Over the past three months, Direxion Daily Semiconductor Bull 3X Shares has recorded a drawdown of -34.85%, reflecting recent price volatility. On average, investors hold Direxion Daily Semiconductor Bull 3X Shares for approximately 6 days, indicating typical investor behavior on the platform.
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
